Pulmonary Aspergillosis: An Analysis of 41 Patients
References (24)
- et al.
Aspergillosis of the lung: an eighteen year experience
Chest
(1971) - et al.
Invasive primary aspergillosis of the lung with cerebral metastasis and complete recovery
Chest
(1962) - et al.
Pulmonary aspergillosis
Ann Thorac Surg
(1972) - et al.
Pulmonary aspergilloma
Ann Thorac Surg
(1975) - et al.
Surgery for pulmonary aspergillosis
J Thorac Cardiovasc Surg
(1969) - et al.
Surgical aspects of pulmonary aspergillosis
J Thorac Cardiovasc Surg
(1974) - et al.
The surgical implications of intracavitary mycetomas (fungus balls)
J Thorac Cardiovasc Surg
(1971) Fungus infection associated with antibiotics and steroid therapy
Am J Med
(1957)- et al.
Serologic tests in diagnosis of aspergillosis
Dis Chest
(1968) - et al.
Bronchopulmonary aspergillosis
Am Rev Resp Dis
(1964)
Secondary aspergillosis
Ann Intern Med
Une nouvelle forme anatomo-radiologique de mycose pulmonaire primitive: le mégamycétome intra bronchiectatique
Arch Med Chir Appar Resp
Cited by (84)
Pulmonary aspergilloma. Clinical aspects and surgical treatment outcome
2012, Thoracic Surgery ClinicsIndications for Surgery in Patients with Localized Pulmonary Infection
2012, Thoracic Surgery ClinicsCitation Excerpt :Even lobectomy for aspergilloma, however, is often difficult because of dense vascular adhesions and pleural fibrosis, which result in relatively high intraoperative blood loss and transfusion rates.9,11 The overall operative mortality rates reported for resection of aspergilloma range from 5.6% to 22.6%.9,11–13,16 Even after lobectomy, the potential postoperative complications that contribute to mortality include hemorrhage, empyema, bronchopleural fistula, and respiratory failure.
Place of surgery in pulmonary aspergillosis and other pulmonary mycotic infections
2012, Revue de Pneumologie CliniquePredictive and prognostic value of preoperative symptoms in the surgical treatment of pulmonary aspergilloma
2010, Journal of Surgical ResearchSurgery for Pulmonary Aspergilloma in Immunocompetent Patients: No Benefit From Adjuvant Antifungal Pharmacotherapy
2010, Annals of Thoracic SurgeryCitation Excerpt :Surgical resection is regarded as the treatment of choice, particularly in symptomatic patients. Previous series reported mortality rates of up to 43% and morbidity mainly from hemorrhage, bronchopleural fistula, and empyema at rates of up to 60% [10, 22, 35]. Thus, surgery was limited to patients with severe life-threatening symptoms.
Presented at the Twenty-second Annual Meeting of the Southern Thoracic Surgical Association, Nov 6–8, 1976, New Orleans, LA.